Cargando…
The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis
BACKGROUND: As the exact pathogenesis of inflammatory bowel disease (IBD) is not known, there is increasing evidence of clinical trials and animal models that indicate the beneficial effects of probiotics. METHODS: Multiple databases were adopted to search for the relevant studies involving the comp...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319782/ https://www.ncbi.nlm.nih.gov/pubmed/30572537 http://dx.doi.org/10.1097/MD.0000000000013792 |
_version_ | 1783385124500406272 |
---|---|
author | Jia, Kai Tong, Xin Wang, Rong Song, Xin |
author_facet | Jia, Kai Tong, Xin Wang, Rong Song, Xin |
author_sort | Jia, Kai |
collection | PubMed |
description | BACKGROUND: As the exact pathogenesis of inflammatory bowel disease (IBD) is not known, there is increasing evidence of clinical trials and animal models that indicate the beneficial effects of probiotics. METHODS: Multiple databases were adopted to search for the relevant studies involving the comparison between probiotics and control groups. Review Manager 5.0 was used to assess the efficacy among included articles. Risk of bias for the articles included was also conducted. RESULTS: Finally, 10 studies eventually met the inclusion criteria and 1049 patients were included. The meta-analyses showed that no significant differences of remission, relapse, and complication rate between Escherichia coli Nissle 1917 and mesalazine groups (RR = 0.94, 95%CI [0.86, 1.03], P = .21; RR = 1.04, 95%CI [0.82, 1.31], P = .77; RR = 1.12, 95%CI [0.86, 1.47], P = .39, respectively). Despite the fact that no significant differences of remission, relapse, and complication rate were observed in overall meta-analysis results between probiotics and placebo group, the subgroup analyses suggested that VSL#3 presented a higher remission rate and lower relapse rate (RR = 1.67, 95%CI [1.06, 2.63], P = .03; RR = 0.29, 95%CI [0.10, 0.83], P = .02, respectively). CONCLUSION: Some types of probiotics, such as E coli Nissle 1917 and VSL#3, could be used as alternative therapy for patients with IBD. |
format | Online Article Text |
id | pubmed-6319782 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-63197822019-01-24 The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis Jia, Kai Tong, Xin Wang, Rong Song, Xin Medicine (Baltimore) Research Article BACKGROUND: As the exact pathogenesis of inflammatory bowel disease (IBD) is not known, there is increasing evidence of clinical trials and animal models that indicate the beneficial effects of probiotics. METHODS: Multiple databases were adopted to search for the relevant studies involving the comparison between probiotics and control groups. Review Manager 5.0 was used to assess the efficacy among included articles. Risk of bias for the articles included was also conducted. RESULTS: Finally, 10 studies eventually met the inclusion criteria and 1049 patients were included. The meta-analyses showed that no significant differences of remission, relapse, and complication rate between Escherichia coli Nissle 1917 and mesalazine groups (RR = 0.94, 95%CI [0.86, 1.03], P = .21; RR = 1.04, 95%CI [0.82, 1.31], P = .77; RR = 1.12, 95%CI [0.86, 1.47], P = .39, respectively). Despite the fact that no significant differences of remission, relapse, and complication rate were observed in overall meta-analysis results between probiotics and placebo group, the subgroup analyses suggested that VSL#3 presented a higher remission rate and lower relapse rate (RR = 1.67, 95%CI [1.06, 2.63], P = .03; RR = 0.29, 95%CI [0.10, 0.83], P = .02, respectively). CONCLUSION: Some types of probiotics, such as E coli Nissle 1917 and VSL#3, could be used as alternative therapy for patients with IBD. Wolters Kluwer Health 2018-12-21 /pmc/articles/PMC6319782/ /pubmed/30572537 http://dx.doi.org/10.1097/MD.0000000000013792 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | Research Article Jia, Kai Tong, Xin Wang, Rong Song, Xin The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis |
title | The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis |
title_full | The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis |
title_fullStr | The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis |
title_full_unstemmed | The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis |
title_short | The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis |
title_sort | clinical effects of probiotics for inflammatory bowel disease: a meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319782/ https://www.ncbi.nlm.nih.gov/pubmed/30572537 http://dx.doi.org/10.1097/MD.0000000000013792 |
work_keys_str_mv | AT jiakai theclinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis AT tongxin theclinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis AT wangrong theclinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis AT songxin theclinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis AT jiakai clinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis AT tongxin clinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis AT wangrong clinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis AT songxin clinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis |